Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

167
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
167
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

156
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
156
Pleiotropy01:33

Pleiotropy

40.4K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
40.4K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

144
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
144
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

152
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
152
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

195
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
195

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolomic Network Analysis Reveals Reorganization of Lipid and Steroid Programs Linked to Right Ventricular-Pulmonary Vascular Function in Pulmonary Hypertension.

bioRxiv : the preprint server for biology·2026
Same author

Clinical Course and Predictors of Heart Failure in Asymptomatic Obstructive Hypertrophic Cardiomyopathy.

Journal of the American Heart Association·2026
Same author

Placental Growth Factor Promotes Endothelial Activation and Inflammatory Remodelling in Pulmonary Hypertension.

Cardiovascular research·2026
Same author

Resolving Diagnostic Discordance in Group 2 Pulmonary Hypertension Through Staged Physiologic Testing: Insights From PVDOMICS.

medRxiv : the preprint server for health sciences·2026
Same author

Phenotypic Characterization of Unclassified Pulmonary Hypertension.

Circulation. Heart failure·2026
Same author

Effect of Dietary Nitrate Supplementation on Exercise Performance in Hypoxic IPF (EDEN-OX3): a double-blind, placebo-controlled, randomised crossover study.

Thorax·2026
Same journal

Beyond the 5th percentile: rethinking diagnostic thresholds in pulmonary function testing.

The European respiratory journal·2026
Same journal

A Transcriptomic Atlas of Chronic Lung Allograft Dysfunction.

The European respiratory journal·2026
Same journal

Risk of cancer and mortality in patients with interstitial lung diseases: Danish cohort study.

The European respiratory journal·2026
Same journal

Proposing a minimal important difference in NTproBNP in pulmonary arterial hypertension.

The European respiratory journal·2026
Same journal

Unlocking growth potential: Ivacaftor therapy and developmental gains in lung and height in a cohort study of children and young adults with cystic fibrosis.

The European respiratory journal·2026
Same journal

Decoding the Lymphangioleiomyomatosis (LAM) Niche Microenvironment <i>via</i> Integrative Analysis of Single Cell Multiomics and Spatial Transcriptomics.

The European respiratory journal·2026
See all related articles

Related Experiment Video

Updated: Jun 22, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.2K

Phenotypes in pulmonary hypertension.

Jason Weatherald1, Anna R Hemnes2, Bradley A Maron3,4

  • 1Department of Medicine, Division of Pulmonary Medicine, University of Alberta, Edmonton, AB, Canada weathera@ualberta.ca.

The European Respiratory Journal
|July 4, 2024
PubMed
Summary
This summary is machine-generated.

Pulmonary hypertension (PH) classification evolves with new phenotypes identified through advanced science. These discoveries improve diagnosis, treatment selection, and clinical trial design for PH patients.

More Related Videos

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.2K
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

20.9K

Related Experiment Videos

Last Updated: Jun 22, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.2K
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.2K
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

20.9K

Area of Science:

  • Cardiology
  • Pulmonology
  • Genomics

Background:

  • The clinical classification of pulmonary hypertension (PH) has historically guided patient management.
  • Recent discoveries in pathobiology and treatment responses have necessitated an evolving classification system.
  • Advances in imaging, computational science, and multi-omics offer new insights into PH heterogeneity.

Purpose of the Study:

  • To explore emerging PH phenotypes and sub-phenotypes informed by recent scientific advancements.
  • To discuss the implications of novel phenotypes for precision medicine and patient stratification.
  • To highlight the potential impact of refined phenotyping on future PH classification, prognostication, and clinical trial design.

Main Methods:

  • Review of current literature on PH classification and phenotyping.
  • Analysis of emerging data from imaging, computational science, and multi-omic studies.
  • Integration of clinical, hemodynamic, and imaging characteristics for phenotyping.

Main Results:

  • Identification of novel phenotypes within pulmonary arterial hypertension (PAH) with distinct molecular profiles.
  • Recognition of PAH patient groups resembling Group 2 (left heart disease) and Group 3 (lung disease) PH.
  • Emergence of severe pulmonary vasculopathy phenotypes within Group 2 and Group 3 PH, distinct from PAH.
  • Sparse application of multi-omic approaches for sub-phenotyping in Group 4 (CTEPH) and Group 5 (sarcoidosis) PH.

Conclusions:

  • The PH classification requires updates to incorporate newly identified phenotypes.
  • Advanced phenotyping, including multi-omics, promises to enhance precision therapies and prognostication for PH.
  • Future iterations of PH classification will likely improve treatment selection and clinical trial design.